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In countries where bancroftian filariasis is endemic,
lymphedema of the leg is a public health problem, particu-
larly for women, who are disproportionately affected. We
investigated the effect of basic lymphedema management
(hygiene, skin care, and lower limb movement and eleva-
tion) on the histologic features of lymphedema. Atotal of 118
skin-punch biopsy specimens were collected from the legs
of 91 patients enrolled in a lymphedema treatment clinic in
Léogâne, Haiti. Follow-up biopsy specimens were collected
from 27 patients ≈12 months later. Keratinocyte hyperprolif-
eration, condensed dermal collagen, and mononuclear
perivascular infiltrate increased with lymphedema stage,
which suggested progressive chronic inflammation and
fibrosis. Follow-up biopsies showed reductions in perivas-
cular mononuclear infiltrate in the superficial dermis (41%
decrease in prevalence), perivascular fibrosis in the deep
dermis (58% decrease), and periadnexal mononuclear infil-
trate (53% decrease). These data suggest that the clinical
improvement commonly observed with basic lymphedema
management has a histologic basis.
L
ymphatic filariasis is an emerging disease in many
areas of the tropics, where vector habitat has expand-
ed because of large-scale water projects and declining san-
itation associated with uncontrolled urban growth (1–3). In
many countries where filariasis has been mapped system-
atically for the first time, its geographic distribution is
much more extensive than previously believed (4,5). In
Haiti, for example, the population at risk for infection was
previously thought to be 1 million persons; however, the
entire country (estimated population, 6–8 million) is now
considered to be at risk (5). 
Lymphedema of the limb is a physically deforming and
socially stigmatizing consequence of filarial infection that
affects ≈15 million persons worldwide (6). Although the
factors responsible for the initiation and progression of
filarial lymphedema to its most severe form, elephantiasis,
have been debated, recurrent episodes of bacterial acute
dermatolymphangioadenitis (ADLA) play a major role
(7–9). Characterized by painful swelling of the limb,
ADLA is accompanied by fever and chills lasting several
days, sometimes with nausea and vomiting (7,8,10). As
lymphedema progresses, the frequency of ADLA episodes
generally increases (11,12). Skin changes of chronic lym-
phedema include thickening, nodular lesions, and pigmen-
tary changes (13,14). Histopathologic studies have found
evidence of inflammatory infiltrate in lymphedematous
tissue (14,15). 
Globally, lymphedema following infection with the
filarial parasite Wuchereria bancrofti is more common in
women than in men (6,16,17). In Haiti, the ratio of affect-
ed women to men is approximately 7 to 1 (16). Reasons for
this discrepancy are unclear but may be related to differ-
ences in the “preferred” anatomic location of the adult
filarial worm between men and women (18) and biologic
factors, particularly pregnancy, that further stress the lym-
phatic system in women. Thus, in many filariasis-endemic
areas, lymphedema is primarily a disease of women. Both
the functional limitations caused by chronic lymphedema
and the short-term impairment that accompanies episodes
of ADLA compromise the ability of women to perform
household chores and to participate in income-generating
activities outside the home, which results in domestic and
economic difficulties for their families and communities
(19–24). 
In 1998, the Global Program to Eliminate Lymphatic
Filariasis embraced lymphedema management as a funda-
mental component of its strategy to eliminate lymphatic
filariasis (25). Based on evidence of the bacterial etiology
of ADLA, current World Health Organization (WHO)
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emphasize basic skin care and hygiene using soap, water,
and antiseptics, as well as elevation of the leg, exercise,
and proper footwear (26). Use of these measures improves
skin condition, decreases the frequency of ADLA attacks,
and reverses or arrests the progression of lymphedema, all
of which improve quality of life (24,27–29).
Few studies in filariasis-endemic areas have examined
stage-specific histologic changes in lymphedematous
skin, and to our knowledge, no previous studies have
examined histologic changes associated with WHO-rec-
ommended management of lymphedema. Our study
attempts to characterize the histopathology of skin at dif-
ferent stages of lymphedema and assess histologic
changes in the lymphedematous legs of patients enrolled
in a lymphedema management program at Hôpital Ste.
Croix in Léogâne, Haiti, an area where bancroftian filari-
asis is highly endemic. 
Materials and Methods
Study Participants
The study protocol and consent forms were approved
by the ethics committee at Hôpital Ste. Croix and the insti-
tutional review board at Centers for Disease Control and
Prevention (CDC). Patients were eligible to participate if
they were enrolled in the lymphedema treatment clinic at
the hospital, had been examined by the clinic physician to
rule out other causes of lower limb swelling, gave
informed consent to collection of all biopsy specimens,
had no medical contraindications to biopsy, had no ADLA
episodes during the previous 2 weeks, and lived within a
10-km radius of the hospital.
Patients were tested for filarial infection by using an
immunochromatographic card test (ICT), which detects
antigen of adult W. bancrofti in the blood (30).
Lymphedema stage was assessed by using an adaptation of
a three-stage system recommended by WHO (31). Stage 1
lymphedema is characterized by swelling that is reversible
on elevation at night. Stage 2 lymphedema is not reversible
upon elevation and has no papillomatous changes. Stage 3
lymphedema, sometimes called elephantiasis, is character-
ized by papillomatous lesions and pronounced der-
matosclerosis. 
Patients were instructed in lymphedema self-care (27),
with emphasis on thorough daily washing of the limb,
basic skin care to treat and prevent entry lesions, range-of-
motion limb exercises, and elevation of the leg during the
day when possible and at night while sleeping. Participants
were provided with basic supplies (e.g., soap, towels, wash
basin) as needed. To monitor lymphedema self-care,
patients returned to the clinic or were visited at home every
4–6 weeks and were asked about compliance with the reg-
imen since the previous visit. Patients were encouraged to
seek antimicrobial drugs and symptomatic treatment at the
hospital during ADLA attacks. Thus, most ADLA attacks
were observed by clinic staff; a few attacks were recorded
on the basis of patient history and the presence of residual
clinical signs (e.g., peeling of the skin, swelling) at the
next follow-up visit.
Biopsy and Analysis
A total of 91 patients agreed to undergo skin-punch
biopsy of their lymphedematous leg or legs, and 26 of
these patients also agreed to a biopsy of their non-lym-
phedematous leg (control). Twenty-seven patients agreed
to have follow-up biopsies of their lymphedematous limb
≈12 months later. Biopsy specimens were taken from the
anterolateral surface of the leg from a site that was repre-
sentative in appearance of the rest of the leg. Irregular pro-
trusions and skin lesions were avoided. After the skin was
cleaned with betadine and anesthetized with 1% lidocaine,
a 4-mm skin-punch biopsy specimen was obtained, and
suture or 3M Steri-Strips were used to close the skin at the
biopsy site. A short course of oral amoxicillin (250 mg
three times a day for 5 days) was given to help prevent
bacterial infection.
Skin-punch biopsy specimens were fixed in formalin in
Léogâne, Haiti, and sent to CDC in Atlanta, Georgia,
where they were embedded in paraffin. Five-micrometer
sections were cut and stained with hematoxylin and eosin.
All biopsy sections were read by the same pathologist
(JG), who was blinded with respect to patient identifica-
tion, lymphedema stage, and whether the specimen was
from an initial or follow-up biopsy. Each biopsy specimen
was evaluated for the presence or absence of the
histopathologic characteristics presented in Table 1.
Statistical Analysis
Statistical analysis was performed using EpiInfo 6.0.
The chi-square and Fischer exact tests were used to com-
pare differences in the proportions of specimens with
histopathologic features.
Results 
Participants
Of the 91 patients enrolled in this study, 73 (80%) were
female. Women and men did not differ significantly with
regard to age, lymphedema stage, or histologic features
(data not shown). Median age was 39 years (range 16–75
years). One patient had bilateral lymphedema; the others
had unilateral disease. Two patients had filarial antigen
detected in the blood by ICT. Both were treated with
diethylcarbamazine, the drug of choice for W. bancrofti
infection. The median length of time between enrollment
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biopsy was 21 days (range 0–866 days).
Microbial Findings
No clinical signs of infection or inflammation were evi-
dent at the biopsy site. Microscopic examination of tissue
sections stained with hematoxylin and eosin revealed no
evidence of bacterial infection and no W. bancrofti adult
worms or microfilariae.
Initial Biopsy Specimens and Histopathologic Features
One hundred eighteen biopsy specimens were collect-
ed, 92 from lymphedematous legs and 26 from nonlym-
phedematous control legs. Biopsy specimens were
collected a median of 14 cm (range 5–20 cm) above the
sole of the foot. The number of biopsy specimens taken
from control legs and from legs with stage, 1, 2, or 3 lym-
phedema was 26, 12, 60, and 20, respectively. No postop-
erative infections developed. Among the biopsy
specimens, the proportion with histopathologic features
(prevalence) increased with lymphedema stage (Table 2).
Epidermis
The prevalence of hyperkeratosis, hypergranulosis, and
acanthosis increased significantly with stage of lymphede-
ma. Hyperkeratosis was the predominant pathologic fea-
ture within the epidermis, regardless of stage, and was
found in 80% of biopsy specimens from legs with stage 3
lymphedema. No biopsy specimens from unaffected con-
trol legs showed hypergranulosis or acanthosis.
Superficial Dermis
Within the superficial dermis, the prevalence of fibro-
lamellar hyperplasia increased from 19% in nonlymphede-
matous legs to 50% in stage 1 lymphedema but remained
similar for stages 1–3. The prevalence of condensed colla-
gen steadily increased from 0% in unaffected control legs
to 30% in stage 2 lymphedema (p = 0.002). Most of the
perivascular infiltrate in the superficial dermis was com-
posed of mononuclear cells, primarily lymphocytes and
macrophages. Plasma cells were found only in stage 2 and
3 lymphedema and were significantly less common in
biopsies from women (4 [4%] of 93) than from men (7
[28%] of 25) (p = 0.002). The prevalence of chronic
mononuclear infiltrate increased steadily from 42% in
nonlymphedematous biopsy specimens to 95% in stage 3
biopsy specimens (p = 0.0002). In all areas where cellular
infiltrate was observed, lymphocyte and macrophage cell
populations were assessed together with respect to infil-
trate intensity because activated lymphocytes were diffi-
cult to differentiate microscopically from macrophages.
The prevalence of pronounced lymphocyte and
macrophage infiltrate increased with lymphedema severi-
ty: 4% of biopsies from nonlymphedematous legs had pro-
nounced infiltrate compared to 35% of stage 3 biopsy
specimens (p = 0.008).
Deep Dermis
Perivascular fibrosis was recorded in 27% and 40% of
skin biopsy specimens from patients with stage 2 and stage
3 lymphedema, respectively; it was more prevalent within
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stage of lymphedema. The prevalence of perivascular infil-
trate, composed entirely of mononuclear cells, increased
from 50% in stage 1 lymphedema to 90% in stage 2
(p = 0.003). Pronounced chronic infiltrate and plasma cells
were also more common in the deep dermis than in the
superficial dermis at every stage of lymphedema. The
prevalence and intensity of periadnexal infiltrate, all of
which was mononuclear, increased with stage of lym-
phedema. Plasma cells were rarely observed in periadnex-
al infiltrate.
Subcutaneous Tissue
All cellular infiltrate in fibrous septa surrounding sub-
cutaneous adipose tissue was mononuclear, and its preva-
lence increased with lymphedema stage, particularly
between nonlymphedematous controls and stage 1 lym-
phedema (4% to 25%). Plasma cells were rarely observed
in the infiltrate surrounding subcutaneous tissue.
Follow-up Participants and Biopsy Specimens
Follow-up biopsy specimens were collected from the
lymphedematous limb of 27 patients a median of 365 days
(range 317–656 days) after their first biopsy. Of these 27
patients, 20 (74%) were women; the median age was 38
years (range 16–61 years). They did not differ significant-
ly by sex, age, or lymphedema stage from the 64 partici-
pants who only had one skin biopsy. 
Compliance with self-care practices during the interval
between biopsies was high. At 96%, 94%, 87%, and 98%
of monthly follow-up visits, respectively, patients reported
that, since the previous visit, they had washed the leg daily,
practiced range-of-motion exercises, elevated the leg dur-
ing the daytime, and raised the foot of the bed at night. No
changes in lymphedema stage were observed.
The second biopsy specimen was obtained a median of
14 cm (range 6–17 cm) above the sole of the foot, and a
median of 1 cm (range <1–5 cm) from the first biopsy site.
No postoperative infections developed. Of the 27 biopsy
specimens that were collected for follow-up, 2 were from
legs with stage 1 lymphedema, 18 from stage 2 lymphede-
ma, and 7 from stage 3 lymphedema. 
Of the 27 patients, 21 (78%) had reported one or more
ADLA attacks during the 12-month period before entering
the program. In contrast, only eight (30%) reported one or
more attacks during the interval between biopsies (1, 4,
and 3 patients with stage 1, 2, and 3 lymphedema, respec-
tively). The mean reported incidence of attacks during the
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person-year, compared to 0.5 (range, 0–3) observed
between biopsies (p = 0.0009).
Histopathologic Changes with 
Lymphedema Management
The prevalence and intensity of histopathologic abnor-
malities tended to be greater in initial skin biopsy speci-
mens (Figure 1A, B, and C) than in follow-up biopsy
specimens (Figure 1D, E, and F) (Table 3). Hyperkeratosis
and hyperplasia of the epidermis were more prominent on
initial specimens (Figure 1A) than on follow-up specimens
(Figure 1D). The thick collagen bundles observed in the
dermis of initial biopsy samples (Figure 1A) were less
obvious in samples after 1 year of lymphedema manage-
ment (Figure 1D). In the superficial dermis, substantial
decreases were observed between the first (Figure 1B) and
second (Figure 1E) biopsies, both in the prevalence of
chronic perivascular infiltrate (100% to 59%, p = 0.0002,
Table 3) and in the proportion of specimens with pro-
nounced infiltrate intensity (37% to 11%, p = 0.03).
Perivascular fibrosis in the deep dermis was less com-
mon in follow-up biopsy samples (22%, Figure 1E) than in
initial samples (52%, Figure 1B). Additionally, significant
decreases were observed in the prevalence of chronic peri-
adnexal infiltrate (70% to 33%, p = 0.007) and the per-
centage of specimens with pronounced infiltrates of
lymphocytes and macrophages in periadnexal areas of the
deep dermis (26% to 0%, p = 0.005, Table 3, and Figures
1C and F). The replacement of thick collagen bundles
around adnexi in the first specimen (Figure 1C) with adi-
pose cells in the second specimen (Figure 1F) was also
noted in the subcutaneous tissue.
Figure 2 summarizes the histologic changes in each of
the 27 patients with follow-up biopsies. Histopathologic
regression or improvement was defined as the disappear-
ance of a histopathologic characteristic on follow-up
specimen, while histopathologic progression or worsening
was defined as the appearance of a previously unnoted
histopathologic characteristic on follow-up specimen. All
but one patient (96%) showed histopathologic regression
in one or more characteristics. Histopathologic improve-
ment was observed among all stages of lymphedema.
However, 4 (57%) of 7 legs with stage 3 lymphedema
showed regression of chronic perivascular infiltrate in the
deep dermis, compared to none of 20 legs with stage 1 or
2 lymphedema (p = 0.003). Eleven (41%) patients showed
regression in four or more characteristics; they did not dif-
fer significantly from the other 16 patients with respect to
sex, age, stage, or duration of lymphedema; duration of
participation in the lymphedema program before the first
biopsy; interval between biopsies; or ADLA incidence
between biopsies (Table 4). Sixteen (59%) patients showed
histopathologic progression in one or more characteristics.
None of the 27 patients had progression of chronic perivas-
cular infiltrate.
Discussion
The physical, personal, social, and economic difficul-
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Figure 1. Representative sample of skin punch biopsy specimens
from patients with lymphedema before (A, B, C) and after (D, E,
F) 1 year of basic lymphedema management. Pretreatment
abnormalities of the epidermis (e), which include increased num-
ber of epithelial cells (acanthosis and epidermal hyperplasia) and
thickening of the keratin (k) layer, were improved after treatment
(compare first [A] and second [D] biopsy specimens from same
patient). Also noted is thickening of collagen bundles (*) in the
dermis on the first (A) sample, which is not observed on the sec-
ond (D). The intensity of inflammatory cells (i), which stain blue,
surrounding fibrosed vessels (v) on the first sample (B), are more
prominent than in the second sample (E). The amount of inflam-
mation (i) in the subcutaneous adipose tissue is also more pro-
nounced in the first biopsy sample (C) than the second sample (F)
where adnexa (ad) with minimal inflammation can be observed.
(Hematoxylin and eosin stains; original magnification for A, C, D,
and F = 25x; B and E = 50x.)ties caused by lymphedema and elephantiasis of the leg in
many filariasis-endemic areas disproportionately affect
women (6,16,17,21,24). Filariasis elimination programs’
increasing adoption of simple, inexpensive measures for
lymphedema management has led to reduced ADLA inci-
dence, reduced lymphedema-related illness, decreased
stigma, and improved quality of life for women in many
filariasis-endemic areas (24,27–29,32). Our study comple-
ments these findings by providing evidence of histologic
improvement in patients who routinely practice lymphede-
ma self-care.
Increasing lymphedema stage was associated with
increased proliferation of keratinocytes and acanthosis in
the epidermis and with an increased prevalence of fibro-
lamellar hyperplasia, condensed collagen, perivascular
fibrosis, and perivascular and periadnexal infiltrate in the
dermis. Epidermal hyperproliferation, which has been
described previously for lymphedema in filariasis-endem-
ic areas (14), can result from an influx of macrophages
that release epidermal growth factors in response to
repeated irritation caused by foreign antigens within the
skin. 
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Figure 2. Individual histologic responses of the 27 patients with follow-up biopsy specimens who participated in a lymphedema man-
agement program for ≈1 year. Black boxes indicate histopathologic regression or improvement, gray boxes indicate histopathologic pro-
gression or worsening, white boxes indicate the absence of histopathologic changes in either biopsy specimens, and boxes with a
diagonal line indicate that histopathologic changes were observed on both initial and follow-up biopsy specimens. Boxes with an X indi-
cate insufficient data.The condensed collagen bundles and perivascular
fibrosis in our biopsy specimens help explain the hardness
of the skin in persons with stage 3 lymphedema. We
observed a progression from thin, lacelike dermal collagen
in biopsy samples from legs with no lymphedema to fibro-
lamellar hyperplasia in the rete ridges accompanied by
thick condensed collagen bundles in patients with severe
lymphedema. In some cases, these collagen bundles
encased vascular vessels as well as adnexal structures.
Lymph stasis, which results from lymphatic dysfunction,
leads to accumulation of blood proteins, cellular metabol-
ic products, and recirculating lymphocytes in the tissue
(33). The presence of these molecules and cells has been
shown to induce epidermal thickening, deposition of colla-
gen in the dermis, and proliferation of fibroblasts (33,34).
The prevalence of mononuclear inflammatory cells
around vessels and adnexa and in the fibrous septa also
increased with lymphedema stage. The inflammatory infil-
trate consisted predominantly of lymphocytes and
macrophages, similar to what has been previously reported
(14,15).The high frequency of plasma cells in the deep der-
mis, present in nearly 60% of stage 1 biopsy specimens, was
unusual and has not been previously reported in patients
with lymphedema in filariasis-endemic areas. Plasma cells
are infrequently found in healthy skin and are generally
associated with chronic inflammation or bacterial infections
(35). The dramatically higher number of plasma cells with-
in the deep dermis suggests a more pronounced immuno-
logic response than in the superficial dermis.
The stimulus for chronic mononuclear infiltrate within
the superficial and deep dermis in these patients is
unknown. Chronic infiltrate may have resulted from poor
clearance by the lymphatic system of bacteria penetrating
the skin surface or a prolonged immune response follow-
ing an ADLA attack. Chronic inflammation might also be
provoked by the presence of macromolecules, the produc-
tion of cytokines and growth factors, and their accumula-
tion in the skin. Studies in filariasis-endemic areas have
shown proinflammatory immune proteins and cytokines in
the serum and lymph fluid of patients with lymphedema
(34).
The fact that specimens from some nonlymphedema-
tous legs had histologic abnormalities, especially chronic
perivascular infiltrate, has several possible explanations.
First, these abnormalities may have been due to minor leg
trauma (i.e., cuts and bruises) or interdigital fungal infec-
tions (27). Of 11 biopsy specimens from nonlymphedema-
tous legs that had perivascular lymphocytes and
macrophages in the superficial dermis, only 1 (9%)
showed pronounced infiltrate. Second, stage 1 lymphede-
ma may have been misclassified as nonlymphedematous in
some cases. Finally, subclinical damage may have already
been present in the legs that appeared normal. 
Atrend toward improvement was noted for virtually all
histologic characteristics examined in the follow-up biop-
sy specimens. The marked improvement in cellular infil-
trate in the superficial dermis is consistent with the effect
of improved skincare and hygiene. In addition, the preva-
lence and intensity of chronic cellular infiltrate surround-
ing adnexa were significantly reduced during the 1-year
period. Taken as a whole, these observations are consistent
with the hypothesis that basic lymphedema management,
which reduced microbial load on the skin surface and
healed entry lesions, led to a decrease in ADLA incidence
and a reduction in chronic inflammation of the skin. 
No changes were observed in lymphedema stage
despite reductions in skin inflammation and fibrosis; how-
ever, the three-stage classification system for lymphedema
provides only a gross assessment of clinical status. A
seven-stage system with better discriminating power (27),
developed after this study was completed, is currently
being used in filariasis-endemic areas. 
At an individual level, we found no factors, including
the absence of ADLAattacks, that were significantly asso-
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be attributed to the limited number of persons in each
group, the prompt use of antimicrobial drugs after onset of
ADLA symptoms, or variation in inflammatory responses
among persons. Acute histologic responses to a single
ADLA attack may have been transient, so that by the time
of the second biopsy, histologic markers of the episode had
cleared. 
This study has several limitations. First, no control
group was included, since ethical considerations precluded
collecting follow-up biopsies from persons not instructed
in lymphedema self-care. However, we would not have
expected to observe significant histopathologic improve-
ment in the absence of intervention. Second, we did not
use special stains for bacteria or immunohistochemical
assays for subtyping cells and collagen, all of which would
be useful for understanding the pathogenesis of lymphede-
ma and are currently planned. Third, the interval between
initiating lymphedema self-care and the first biopsy varied
among patients; the first biopsy specimens was not always
a “baseline” specimen. However, this variation did not
appear to influence the degree of histologic improvement
during follow-up, which suggests that the benefits of lym-
phedema management are not limited to the first few
months but continue to accrue with practice. Finally, the
number of patients included in the follow-up study was
small, which limited statistical power. Larger studies,
preferably involving several centers, are recommended.  
In conclusion, participation in a lymphedema manage-
ment program for 1 year was associated with significant
reductions in cellular infiltrate and fibrosis. Lymphedema
management, based on inexpensive and practical elements
of self-care at home, can lead not only to histologic
improvement, as shown here, but also to clinical and func-
tional benefits and to improved quality of life. Programs in
Brazil (27), India (29), Haiti (24,32), Guyana (28), and
elsewhere have documented these benefits and pioneered
creative ways, such as support groups (32), to teach affect-
ed women the principles of lymphedema self-care and
motivate them to continue to practice it. In most filariasis-
endemic areas, however, such programs do not yet exist. To
reach the millions of women who suffer from this disease,
lymphedema management must be expanded, as an integral
part of the Global Program to Eliminate Lymphatic
Filariasis, to all major filariasis-endemic areas worldwide.
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